2006
Neoadjuvant paclitaxel (P), carboplatin (Ca) and gemcitabine (G) in patients with locally advanced transitional cell carcinoma (TCC) of the bladder: A final report
Smith D, Mackler N, Hussain M, Dunn R, Montie J, Wood D, Lee C, Petrylak D, Quinn D, Vaishampayan U. Neoadjuvant paclitaxel (P), carboplatin (Ca) and gemcitabine (G) in patients with locally advanced transitional cell carcinoma (TCC) of the bladder: A final report. Journal Of Clinical Oncology 2006, 24: 4541-4541. DOI: 10.1200/jco.2006.24.18_suppl.4541.Peer-Reviewed Original ResearchTransitional cell carcinomaAdvanced transitional cell carcinomaPT0 rateArm IArm IITreatment of TCCGrade 3/4 hematologic toxicitiesM0 transitional cell carcinomaAdequate organ functionCycles of therapyGrade 3 toxicityPerformance status 0Pathologic complete respondersNational Cancer InstituteBristol-Myers SquibbNeoadjuvant paclitaxelStatus 0Complete respondersEvaluable subjectsHematologic toxicityNeoadjuvant chemotherapyPrimary endpointPositive patientsResection rateClinical T3
2002
Higher doses of mitoxantrone among men with hormone‐refractory prostate carcinoma
Levine EG, Halabi S, Roberts JD, Kaplan EB, Rago R, Atkins JN, Vogelzang NJ. Higher doses of mitoxantrone among men with hormone‐refractory prostate carcinoma. Cancer 2002, 94: 665-672. PMID: 11857298, DOI: 10.1002/cncr.10217.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate carcinomaHigh dosesPelvic irradiationProstate carcinomaArm IFrequency of thrombocytopeniaLow-dose glucocorticoidsArm IIPhase II trialPhase III trialsPhase III testingMedian survival timeGranulocyte-macrophage colony-stimulating factorColony-stimulating factorAssessable patientsEstramustine combinationsII trialIII trialsMedian survivalPartial responsePSA valuesFavorable outcomeSurvival timePatientsSame schedule
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply